OVID

Ovid Therapeutics Inc.
CAPPED RATING

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics Inc. (OVID) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D-). The rating has held at C- for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
D-
Factor Score 1.0 / 5.0
Growth
D-
Factor Score 1.0 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.3
EV / EBITDA -5.2
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -12.1%
Price Return 12M 92.4%
Catalyst Signal 0.00
Market Cap $479.4M
TTM Revenue $1.5M
Price / Sales 329.9
ROE -35.4%

Historical Factor Score Progression

Held C- for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 D- (1.0) D- (1.0) B- (3.1) C+ (2.6) C+ (2.6) C- (2.1)
2026-11-07 D- (1.0) D- (0.8) B (3.2) B- (2.9) C+ (2.7) C- (2.1)
2026-10-31 D- (1.1) D- (0.7) B- (3.1) B- (3.0) C+ (2.7) C- (2.1)
2026-10-24 D (1.4) D- (0.8) B- (3.1) C+ (2.7) C+ (2.6) C- (2.1)
2026-10-17 D (1.4) D- (0.8) B- (3.1) C+ (2.8) C+ (2.6) C- (2.1)
Page 1 of 8
…